The in vivo studies were limited by the use of a single mouse model, a suboptimal dosing regimen, and only two specific GPR84 agonists, suggesting the need for more physiologically relevant models, optimized dosing strategies, and a broader range of agonists to fully evaluate the potential of GPR84 activation in CRC therapy. This evidence concerns the gene GPR84 and colorectal carcinoma.